Skip to content
value.today
Kalaris Therapeutics, Inc. logo

Kalaris Therapeutics, Inc.

KLRS
$45 Mmarket cap on Oct 26, 2026-42.2% since Jan 2024
1M
-35.5%
Compare
World rank
#21,699
Revenue
—
For year ending December-2025
Net income
$-43 M
SEC filing
Employees
107
As on 2021
value.today research

Kalaris Therapeutics, Inc. in brief

Kalaris Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Massachusetts, USA. Its market value was $45 M on 26 October 2026, which makes it the 21,699th largest listed company in the world and the 3,909th largest in the USA on this site. It employs about 107 people. Its shares trade under the symbol KLRS (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Kalaris Therapeutics, Inc.

AlloVir is a Late Clinical Stage Cell Therapy company. The company annual revenue is 49.9 million USD and 21 employees as on 2020. The headquarters is in USA.

Kalaris Therapeutics, Inc. timeline

5 events, 2018–2025
  1. 2018
  2. ✎
    Renamed Allovir, Inc.
    Formerly ViraCyte, Inc..
  3. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  4. 2020
  5. 🔔
    · approximate
    Initial public offering on Nasdaq
  6. 🔔
    Initial public offering as Allovir, Inc.
    Final prospectus filed with the SEC on 30 July 2020; shares registered for exchange trading on 27 July 2020.
  7. 2025
  8. ✎
    Renamed Kalaris Therapeutics, Inc.
    Formerly Allovir, Inc..

Events of Kalaris Therapeutics, Inc. from SEC EDGAR and the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$640 M$1.3 B$1.9 B$2.6 B202120222023202420252026

World rank over time

▼ down 16,783 places since 2021
2021-01-01: #4957#4,95720212022-01-07: #11023#11,02320222022-12-25: #15386#15,38620222023-07-30: #15119#15,11920232024-01-05: #22735#22,73520242026-09-30: #20204#20,20420262026-10-26: #21740#21,7402026

Rank in USA: #1,541 (Jan 2021) · #2,821 (Jan 2022) · #3,155 (Dec 2022) · #3,066 (Jul 2023) · #3,863 (Jan 2024) · #3,695 (Sep 2026) · #3,913 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
0.6×
Free cash flow yield
-86.6%
Net margin
—
Operating margin
—
Return on equity
-55.1%
Liabilities / assets
35.3%
R&D / revenue
10156.3%
Profit per employee
$-406 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2019: revenue $0M, net income $-24M$0MFY19Fiscal year ending Dec 2020: revenue —, net income $-70M—FY20Fiscal year ending Dec 2021: revenue —, net income $-172M—FY21Fiscal year ending Dec 2022: revenue —, net income $-169M—FY22Fiscal year ending Dec 2023: revenue —, net income $-190M—FY23Fiscal year ending Dec 2024: revenue —, net income $-69M—FY24Fiscal year ending Dec 2025: revenue —, net income $-43M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-46M$-43M—
Dec 2024——$-52M$-69M—
Dec 2023——$-200M$-190M—
Dec 2022——$-171M$-169M—
Dec 2021——$-170M$-172M—
Dec 2020——$-71M$-70M—
Dec 2019$0M—$-27M$-24M-14900.0%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-38M$0M$-39M$-2.85—
Dec 2024$-21M——$-51.77—
Dec 2023$-124M——$-42.09—
Dec 2022$-142M——$-2.20—
Dec 2021$-106M$0M$-106M$-2.74—
Dec 2020$-61M$0M$-61M$-2.59—
Dec 2019$-20M$0M$-21M$-18.54—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-22M—Dec ’24Three months to Mar 2025: revenue —, net income $-10M—Mar ’25Three months to Jun 2025: revenue —, net income $-11M—Jun ’25Three months to Sep 2025: revenue —, net income $-12M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-10M—Dec ’25Three months to Mar 2026: revenue —, net income $-11M—Mar ’26Three months to Jun 2026: revenue —, net income $-12M—Jun ’26Three months to Sep 2026: revenue —, net income $-11M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-11M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Kalaris Therapeutics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-46 M
Net income
$-43 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$122 M
Total liabilities
$43 M
Total equity
$79 M

As of December-2025

Top 54 institutional investors in Kalaris Therapeutics, Inc.#

As of Sep 30, 2026
54 institutions held 17.2 M shares (about 72.4% of the shares outstanding) on Sep 30, 2026. The ten largest hold 67.7%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Kalaris Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Samsara Biocapital, LLC12,881,1750 (0.00%)54.11%$37 MNov 16, 2026
2RTW Investments, LP1,300,0000 (0.00%)5.46%$4 MNov 16, 2026
3Alyeska Investment Group, L.P.472,687-100,000 (-17.46%)1.99%$1 MNov 16, 2026
4Siren, L.L.C.356,559-79,239 (-18.18%)1.50%$1 MNov 12, 2026
5Vanguard Capital Management LLC330,928-67,784 (-17.00%)1.39%$1 MNov 13, 2026
6Ikarian Capital, LLC248,257-111,743 (-31.04%)1.04%$1 MNov 16, 2026
7Renaissance Technologies LLC176,863+27,512 (+18.42%)0.74%$1 MNov 12, 2026
8Verdad Advisers, LP140,232+59,935 (+74.64%)0.59%$0 MNov 16, 2026
9UBS Group AG110,187-151,944 (-57.96%)0.46%$0 MNov 10, 2026
10Raymond James Financial Inc101,496+4,332 (+4.46%)0.43%$0 MNov 12, 2026
11WHI TRUST Co LLC97,4930 (0.00%)0.41%$0 MNov 12, 2026
12Woodline Partners LP90,000-10,000 (-10.00%)0.38%$0 MNov 16, 2026
13Geode Capital Management, LLC78,859-35,178 (-30.85%)0.33%$0 MNov 6, 2026
14Boothbay Fund Management, LLC63,623-28,638 (-31.04%)0.27%$0 MNov 16, 2026
15ADAR1 Capital Management, LLC60,000-40,000 (-40.00%)0.25%$0 MNov 16, 2026
16BlackRock, Inc.58,619+4,177 (+7.67%)0.25%$0 MNov 13, 2026
17State Street Corp51,210+24,700 (+93.17%)0.22%$0 MNov 12, 2026
18Vanguard Fiduciary Trust Co47,553-18,626 (-28.14%)0.20%$0 MNov 13, 2026
19Belpointe Asset Management LLC40,0000 (0.00%)0.17%$0 MNov 9, 2026
20Fortis Capital Advisors, LLC40,0000 (0.00%)0.17%$0 MNov 9, 2026
21Goldman Sachs Group Inc39,616+23,562 (+146.77%)0.17%$0 MNov 16, 2026
22Citadel Advisors LLC39,219-56,553 (-59.05%)0.16%$0 MNov 16, 2026
23Connor, Clark & Lunn Investment Management Ltd.35,678+5,671 (+18.90%)0.15%$0 MNov 10, 2026
24Stonepine Capital Management, LLC33,842+3,720 (+12.35%)0.14%$0 MNov 13, 2026
25Morgan Stanley26,773-45,553 (-62.98%)0.11%$0 MNov 13, 2026
Show all 54: investors 26 to 54
Institutional investors 26 to 54 in Kalaris Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Northern Trust Corp25,833-6 (-0.02%)0.11%$0 MNov 16, 2026
27HRT Financial LP25,560+11,837 (+86.26%)0.11%$0 MNov 13, 2026
28Velan Capital Investment Management LP25,0000 (0.00%)0.10%$0 MNov 16, 2026
29WealthTrust Asset Management, LLC23,604+3,188 (+15.62%)0.10%$0 MOct 22, 2026
30Quadrature Capital Ltd23,287+6,760 (+40.90%)0.10%$0 MNov 13, 2026
31Bridgeway Capital Management, LLC22,500-10,000 (-30.77%)0.09%$0 MNov 16, 2026
32Empowered Funds, LLC22,500New0.09%$0 MNov 13, 2026
33Jane Street Group, LLC19,594New0.08%$0 MNov 12, 2026
34Squarepoint Ops LLC18,947-19,828 (-51.14%)0.08%$0 MNov 9, 2026
35RBF Capital, LLC17,3910 (0.00%)0.07%$0 MNov 13, 2026
36Dimensional Fund Advisors LP15,9580 (0.00%)0.07%$0 MNov 4, 2026
37XTX Topco Ltd14,726New0.06%$0 MNov 16, 2026
38Nano Cap New Millennium Growth Fund L P14,000+1,500 (+12.00%)0.06%$0 MNov 13, 2026
39Independent Advisor Alliance12,625-5,500 (-30.34%)0.05%$0 MNov 10, 2026
40FMR LLC7,8060 (0.00%)0.03%$0 MNov 10, 2026
41Federation des caisses Desjardins du Quebec6,000New0.03%$0 MNov 16, 2026
42Nuveen, LLC4,639New0.02%$0 MNov 10, 2026
43Caitong International Asset Management Co., Ltd1,559+1,552 (+22171.43%)0.01%$0 MOct 29, 2026
44Tower Research Capital LLC (TRC)838-1,722 (-67.27%)0.00%$0 MNov 16, 2026
45Vanguard Global Advisers, LLC7250 (0.00%)0.00%$0 MNov 13, 2026
46Strengthening Families & Communities, LLC2680 (0.00%)0.00%$0 MOct 21, 2026
47Jpmorgan Chase & Co500 (0.00%)0.00%$0 MNov 12, 2026
48BNP Paribas Financial Markets46-6 (-11.54%)0.00%$0 MNov 12, 2026
49Steward Partners Investment Advisory, LLC21-2,194 (-99.05%)0.00%$0 MNov 13, 2026
50Barclays PLC17-286 (-94.39%)0.00%$0 MNov 6, 2026
51Royal Bank Of Canada14+2 (+16.67%)0.00%$0 MNov 16, 2026
52Harbour Investments, Inc.130 (0.00%)0.00%$0 MNov 9, 2026
53SBI Securities Co., Ltd.50 (0.00%)0.00%$0 MOct 22, 2026
54Citigroup Inc1New0.00%$0 MNov 4, 2026

Mutual funds holding Kalaris Therapeutics, Inc.#

19 funds hold shares worth $2 M (about 2.3% of the company). Since their previous reports 12 added shares and 1 sold, buying $1 M net.
Mutual funds holding Kalaris Therapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.255,337$1 M1.1%<0.01%+44%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.137,373$1 M0.58%<0.01%+89%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC34,574$0 M0.15%<0.01%+1.8%May 31, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC32,500$0 M0.14%0.09%+44%Jun 30, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors25,924$0 M0.11%<0.01%+198%Jun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC16,829$0 M0.07%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC9,885$0 M0.04%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC9,575$0 M0.04%<0.01%+8.1%May 31, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.8,020$0 M0.03%<0.01%−4.9%Jun 30, 2026
🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC7,806$0 M0.03%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.6,002$0 M0.03%<0.01%no changeJun 30, 2026
🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP3,296$0 M0.01%<0.01%newJul 31, 2026
🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP2,750$0 M0.01%<0.01%newJul 31, 2026
🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP2,614$0 M0.01%<0.01%newJul 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC1,725$0 M<0.01%<0.01%+184%Jun 30, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.911$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 LVIP Dimensional U.S. Core Equity 2 FundLincoln Financial Investments Corporation135$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC79$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC47$0 M<0.01%<0.01%+6.8%Jul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 19 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Kalaris Therapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$6.2 M
2 purchases, 2 insiders
Sold, 12 months
$13 K
1 sale, 1 insider
Net, 12 months
$6.2 M
open market only
Insiders on file
27
since
$5.0 M-$66 K$0Nov 2023: bought $0 (0 trades), sold $17 K (4 trades)Nov 23Dec 2023: bought $0 (0 trades), sold $21 K (1 trades)Jan 2024: bought $0 (0 trades), sold $12 K (8 trades)Jan 24Feb 2024: bought $0 (0 trades), sold $66 K (10 trades)Apr 2024: bought $0 (0 trades), sold $14 K (11 trades)AprMay 2024: bought $0 (0 trades), sold $25 K (9 trades)Jul 2024: bought $0 (0 trades), sold $14 K (11 trades)JulAug 2024: bought $0 (0 trades), sold $24 K (9 trades)Oct 2024: bought $0 (0 trades), sold $15 K (11 trades)OctNov 2024: bought $0 (0 trades), sold $24 K (8 trades)Jan 2025: bought $0 (0 trades), sold $2 K (9 trades)Jan 25Feb 2025: bought $0 (0 trades), sold $5 K (3 trades)Mar 2025: bought $0 (0 trades), sold $8 K (1 trades)MarDec 2025: bought $5.0 M (1 trades), sold $0 (0 trades)Mar 2026: bought $0 (0 trades), sold $13 K (1 trades)MarMay 2026: bought $1.2 M (1 trades), sold $0 (0 trades)
Bought (open market)Sold (open market)Hover a month for the totals
Kalaris Therapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed BioCapital L.p. Samsara10% ownerBuyindirect+244,300$4.830$1.2 M2.22 MForm 4
filed BioCapital L.p. Samsara10% ownerOtherindirect-66,906——10.66 MForm 4
filed BioCapital L.p. Samsara10% ownerOtherindirect+14,937——14,937Form 4
filed BioCapital L.p. Samsara10% ownerOtherindirect+4,471——19,408Form 4
filed Brett R. HagenChief Accounting OfficerSell-1,915$6.720$13 K0Form 4
filed Srinivas AkkarajuDirector, 10% ownerGrant or awardindirect+1.50 M$10.00$15.0 M1.50 MForm 4
filed Samsara Opportunity Fund, L.P.10% ownerBuyindirect+479,847$10.42$5.0 M1.98 MForm 4
filed Brett R. HagenChief Accounting OfficerSell-907$8.970$8 K1,925Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Kalaris Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
366,632
1.6% of shares · 5.43 days to cover
Shares sold short, last 24 reportsAll stocks →

Trading halts

  • 2025-09-03 15:28 UTC, code LUDP, resumed 15:38 UTC
  • 2025-09-03 15:23 UTC, code LUDP, resumed 15:28 UTC
  • 2025-09-03 15:10 UTC, code LUDP, resumed 15:20 UTC
  • 2025-09-03 14:56 UTC, code LUDP, resumed 15:01 UTC
  • 2025-04-10 15:42 UTC, code LUDP, resumed 15:47 UTC

Fails to deliver

  • : 58 shares at $1.87
  • : 364 shares at $2.90
  • : 13,446 shares at $3.25
  • : 17,820 shares at $3.20
  • : 1,194 shares at $3.16

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Kalaris Therapeutics, Inc. scorecard#

Passes 3 of the 11 checks that could be worked out: strongest in financial health (1 of 3), weakest in valuation (1 of 4). Fiscal year 2025; market cap of Oct 26, 2026.

  • Valuation1 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median0.6×Price to book 0.6× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-86.6%Free cash flow is -86.6% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-2.85 vs -51.77Diluted EPS -2.85 in fiscal 2025 against -51.77 the year before (report's currency).
    • ✓Net income higher than five years earlier-$43 M-$43 M in fiscal 2025 against -$70 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 2
    • ✗Profitable in the newest year-$43 MNet income -$43 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities12.2×Current ratio 12.24 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • ✗Operating income covers interest five times-32.0×Operating income -32.0 times interest in fiscal 2025.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Kalaris Therapeutics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Kalaris Therapeutics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019
Income statement
Revenue——————0.2
Research and development3145r1331191215016
General and administrative156.7r4852492211
Operating expenses4652r2001711707127
Operating income−46−52r−200−171−170−71−27
Interest and finance income—5.55.71.91.31.32.1
Interest expense and finance costs1.42.7—————
Other non-operating income (expense)2.7−17r3.60.4−2.50.20.8
Income before tax−43−69r−191−169−171−70−24
Income tax00−0.1−0.31.0——
Net income including minority interests−43−69r−190−169−172−70−24
Net income attributable to shareholders−43−69r−190−169−172−70−24
Earnings per share, basic-2.85-51.77r-42.09r-2.20-2.74-2.59-18.54
Earnings per share, diluted-2.85-51.77r-42.09r-2.20-2.74-2.59-18.54
Shares, weighted average (basic)151.3r4.5r7763——
Shares, weighted average (diluted)151.3r4.5r7763271.3
Balance sheet
Cash and cash equivalents981.6r9010620212361
Short-term investments200941284623465
Other current assets0.81.0r3.57.15.24.50.7
Current assets1192.6r188243253361127
Property, plant and equipment———0.91.50.80.4
Right-of-use (leased) assets1.502.232308.712
Total assets1226.2r191277287371139
Accounts payable1.31.6r6.83.08.41.00.6
Current liabilities9.725r282438129.1
Lease liabilities (non-current)1.101728235.58.7
Total liabilities4357r4553611818
Retained earnings−160−117r−656−466−297−125−55
Shareholders' equity79−97r−45r225225353−52
Total liabilities and equity1226.2r191277287371139
Shares outstanding231.4r5.0r9364622.1
Cash-flow statement
Depreciation and amortization——0.40.70.20.10.0
Share-based compensation1.90.9r4141449.42.9
Cash from operating activities−38−21r−124−142−106−61−20
Capital expenditure−0.2———−0.0−0.2−0.3
Cash from investing activities−209538−80186−169−65
Shares issued42——126———
Cash from financing activities15519r701270.2292121
Exchange-rate effect on cash————−0.0−0.1—
Change in cash97−1.5r−16−96806236
Report10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Where Kalaris Therapeutics, Inc. operates: 3 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 3 subsidiaries on file.

Kalaris Therapeutics, Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters1 office1 subsidiary—
🇮🇪 Ireland1 subsidiary—
🇮🇹 Italy1 subsidiary—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Executive pay at Kalaris Therapeutics, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$2.6 M
Andrew Oxtoby, Vikas Sinha
Other top executives, average
$1.4 M
the CEO earned 1.8× this
$100 invested is now
$54
Kalaris Therapeutics, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Andrew Oxtoby, Vikas Sinha$2.6 M$4.5 M$1.4 M$54
2024Diana Brainard, Vikas Sinha$3.0 M$2.8 M$721 K$62

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Kalaris Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Change in control 1 · Acquisition or sale completed 1 · Directors and officers 9 · Material agreement 2 · Unregistered share sale 1 · Shareholder rights changed 1 · Bylaws or fiscal year changed 2 · Shareholder vote 4 · Results announced 8

Kalaris Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Shareholder vote8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Change in controlAcquisition or sale completedDirectors and officersBylaws or fiscal year changedResults announced8-K
Directors and officersShareholder vote8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Shareholder vote8-K
Directors and officers8-K
Material agreement8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026

Acquisitions and funding#

2 private funding rounds before listing

Private share sales · funding history

Private share sales of Kalaris Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2019$121 MNo. 2$50 to $250 million47equitySEC
Sep 2018$30 MNo. 1$10 to $50 million1equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Layoffs at Kalaris Therapeutics, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
0
2024–2024
Latest
—
2024-01-01
Kalaris Therapeutics, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2024············—
Kalaris Therapeutics, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
95% of workforceRestructuring planSEC 8-K“(“AlloVir”) approved a reduction its workforce by approximately 95% of AlloVir’s current employee base in order to reduce costs and preserve capital in light of AlloVir’s announcem…”Filing

Source: State WARN notices and SEC 8-K item 2.05

How Kalaris Therapeutics, Inc. compares in Biotechnology

  • Market cap$45 M · higher than 24% of 726
  • Price / book0.6× · lower than 90% of 534
  • FCF yield-86.6% · higher than 12% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Kalaris Therapeutics, Inc.🇺🇸$45 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 26, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As on 2021
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Kalaris Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Kalaris Therapeutics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Kalaris Therapeutics, Inc.? Suggest a correction